Please login to the form below

Not currently logged in
Email:
Password:

GSK's Cervarix HPV vaccine approved in Kenya

GlaxoSmithKline's HPV vaccine Cervarix is now available in Kenya after the country's Pharmacy and Poison's Board approved it for marketing

GlaxoSmithKline's (GSK) human papillomavirus (HPV) vaccine Cervarix has become available in Kenya after the country's Pharmacy and Poison's Board approved it for marketing.

Cervarix has been shown to be 100 per cent effective in preventing infection with HPV strains 16 and 18, which together cause about 70 per cent of cervical cancer cases.

Kenya is now the third country after Australia and the United Arab Emirates to approve marketing of Cervarix after the pharmacy board approved GSK's application in June 2007.

GSK has not yet revealed the price of the vaccine in the country, but it may cost in the region of USD 300, according to local media reports. Other reports say that Kenyans will be unable to afford the vaccine and that the government would lobby health donors to buy bulk quantities of Cervarix. The Kenyan government does not have the authority to issue price controls for the vaccine.

Director of medical and regulatory affairs in East Africa for GSK, William Mwatu, said that the company was continuing to assess the cost and supply details of Cervarix in Kenya.

3rd September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Waiting room
Immunotherapy combination trials Q&A
By Chris Learn and Martin Lachs...

Infographics